Clearmind Completes Recruitment for First Alcohol Use Disorder Cohort in CMND-100 Phase I/IIa Trial

• Clearmind Medicine completed recruitment for the first alcohol use disorder cohort in its Phase I/IIa trial of CMND-100.
• Part B will evaluate patients with moderate-to-severe disease, assessing safety, tolerability and potential reductions in alcohol craving.
• The study follows completed testing in healthy volunteers, for which safety and tolerability data have already been reported.
• Part B will generate the first clinical results evaluating CMND-100 in patients with alcohol use disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270822PRIMZONEFULLFEED9853912) on October 27, 2026, and is solely responsible for the information contained therein.